Entera Health, Inc. Announces Presentations at the 2014 Annual Meeting of The American College Of Gastroenterology (ACG)

Share Article

Four presentations will be hosted by Entera Health at the 2014 Annual Meeting American College Of Gastroenterology (ACG) in Philadelphia, PA, Friday, October 17th - Wednesday, October 22nd.

Entera Health

Entera Health Inc. is pleased to announce the following important presentations taking place next week at ACG 2014:

ACG 2014
Product Theater - "A Novel Approach to Managing Enteropathy"
Monday, October 20th
(10:30-11:30am)
Location: Pennsylvania Convention Center, ACG Exhibit Hall, Booth #1049

ACG 2014
Poster ID: P507
Sunday, Oct. 19th
(4:30 pm – 6:00 PM)     A Case of Short Bowel Syndrome Managed With a Prescription Medical Food Product, Serum-Derived Bovine Immunoglobulin/Protein Isolate (SBI).
Raouf Hilal, MD, University of Central Florida Medical School, Orlando, FL

ACG 2014
Poster ID: P1113
Monday, Oct. 20th (12:45 - 2:15 PM)     Fecal Incontinence With Chronic Mesenteric Ischemia: Case Report in Response to Serum-Derived Bovine Immunoglobulin/Protein Isolate.
Larry Good, MD, South Nassau Communities Hospital, Oceanside, NY

ACG 2014
Poster ID: P1698
Tuesday, Oct 21st (12:45 – 2:15 PM)     Use of Serum-Derived Bovine Immunoglobulin/Protein Isolate (SBI) to Manage Refractory Ulcerative Colitis Symptoms and Avoid Surgery.
Gerald Dryden, MD, School of Medicine - University of Louisville, Louisville, KY

To learn more, please visit Entera Health at Booth #315.

About EnteraGam™
EnteraGam™ (serum-derived bovine immunoglobulin/protein isolate, SBI) is a prescription medical food product indicated for the clinical dietary management of enteropathy [e.g., in diarrhea-predominant irritable bowel syndrome (IBS-D) and HIV-associated enteropathy]. EnteraGam™ is required to be used under physician supervision as part of ongoing medical care for a specific condition or disease. EnteraGam™ is also indicated for the clinical dietary management of enteropathy in patients who, because of therapeutic or chronic medical needs, have limited or impaired capacity to ingest, digest, absorb, or metabolize ordinary foodstuffs or certain nutrients. For full prescribing information, please visit our product website at http://enteragam.com/.

Important Safety Information
EnteraGam™ is a specially formulated protein source for the management of intestinal disorders. The product has been extremely well tolerated for up to a year in HIV patients and up to 8 months in infants. The major side effects in clinical trials (2-5%) have included mild nausea, constipation, stomach cramps, headache, and increased urination. EnteraGam™ is contraindicated for patients with a hypersensitivity (allergy) to beef, or any components in EnteraGam™. Therefore, patients who have an allergy to beef or any component of EnteraGam™ should not take this product. EnteraGam™ has not been studied in pregnant and nursing mothers. The choice to administer EnteraGam™ in pregnant or nursing mothers is at the clinical discretion of the physician. Medical foods like EnteraGam™ are required by FDA regulations to be dosed and monitored by physicians as part of ongoing care for patients with chronic conditions or diseases.

About Entera Health, Inc.
Entera Health, Inc. is focused on improving worldwide health through the development of clinically safe biotherapeutics to address unmet needs. Our passion is to help people thrive through healthier living. Our motivation for conducting basic research, clinical studies, and appropriately educating patients and healthcare providers is driven to meet this goal. Visit us at http://www.enterahealth.com/.

For questions, please contact:
Tom Heck, Chief Operating Officer
515-963-7560
tom.heck(at)enterahealth.com

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Tom Heck, Chief Operating Officer
Entera Health
+1 (515) 963-7560
Email >
Visit website